Drug name - Ibrance

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7208489 PFIZER 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
Jan, 2023

(3 months from now)

US6936612 PFIZER 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
Jan, 2023

(3 months from now)

USRE47739 PFIZER 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
Mar, 2027

(4 years from now)

US10723730 PFIZER Solid forms of a selective CDK4/6 inhibitor
Feb, 2034

(11 years from now)

CN105008357A PFIZER Solid State Form Of Selective Cdk4/6 Inhibitor
Jul, 2020

(2 years ago)

CN101906104B PFIZER 2-(Pyridin-2-Yl Amino)-Pyrido [2, 3-D] Pyrimidin-7-Ketone
Jan, 2023

(3 months from now)

CN101001857B PFIZER 2-(Pyridine-2-Ylamio)-Pyrido[2,3-D]Pyrimidin-7-Ketone
Jan, 2023

(3 months from now)

CN102295643B PFIZER 2-(Pyridine-2-Ylamio)-Pyrido[2,3-D]Pyrimidin-7-Ketone
Jan, 2023

(3 months from now)

CN102295643A PFIZER 2-(Pyridine-2-Ylamio)-Pyrido[2,3-D]Pyrimidin-7-Ketone
Jan, 2023

(3 months from now)

CN101001857A PFIZER 2-(Pyridine-2-Yl Amido)-Pyridino[2,3-D]Pyrimidine-7-Ketone
Jan, 2023

(3 months from now)

CN101906104A PFIZER 2-(Pyrid-2-Ylamino)-Pyridino[2,3-D] Pyrimidine-7-One
Jan, 2023

(3 months from now)

IN200401733P1 PFIZER 2-(Pyridin-2-Ylamino)-Pyrido(2,3-D)Pyrimidin-7-Ones
Jan, 2023

(3 months from now)

IN218291B PFIZER 2-(Pyridin-2-Ylamino)-Pyrido(2,3-D)Pyrimidin-7-Ones
Jan, 2023

(3 months from now)

EP1470124B1 PFIZER 2-(Pyridin-2-Ylamino)-Pyrido 2,3-D Pyrimidin-7-Ones
Jan, 2023

(3 months from now)

EP1470124A1 PFIZER 2-(Pyridin-2-Ylamino)-Pyrido 2,3-D]Pyrimidin-7-Ones
Jan, 2023

(3 months from now)

EP2958916B1 PFIZER Solid Forms Of A Selective Cdk4/6 Inhibitor
Feb, 2034

(11 years from now)

EP2958916A1 PFIZER Solid Forms Of A Selective Cdk4/6 Inhibitor
Feb, 2034

(11 years from now)

EP3431475A1 PFIZER Solid Forms Of A Selective Cdk4/6 Inhibitor
Feb, 2034

(11 years from now)

EP3431475B1 PFIZER Solid Forms Of A Selective Cdk4/6 Inhibitor
Feb, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456168 PFIZER 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones Jan, 2023

(3 months from now)

US11065250 PFIZER Solid dosage forms of palbociclib May, 2036

(13 years from now)

Drugs and Companies using PALBOCICLIB ingredient

Treatment: Palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men, or with fulvestrant in pts with disease progression after endocrine therapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
75MG CAPSULE;ORAL Prescription
100MG CAPSULE;ORAL Prescription
125MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.